Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Lung cancer is the leading cause of cancer-related deaths worldwide. The majority of lung cancers are non-small cell lung cancer (NSCLC), accounting for approximately 85% of all lung cancer types. The Cox proportional hazards model (CPH), which is the standard method for survival analysis, has several limitations. The purpose of our study was to improve survival prediction in patients with NSCLC by incorporating prognostic information from F-18 fluorodeoxyglucose positron emission tomography (FDG PET) images into a traditional survival prediction model using clinical data.
Results: The multimodal deep learning model showed the best performance, with a C-index and mean absolute error of 0.756 and 399 days under a five-fold cross-validation, respectively, followed by ResNet3D for PET (0.749 and 405 days) and CPH for clinical data (0.747 and 583 days).
Conclusion: The proposed deep learning-based integrative model combining the two modalities improved the survival prediction in patients with NSCLC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903435 | PMC |
| http://dx.doi.org/10.1186/s12859-023-05160-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The survival analysis of stage III and IV inoperable lung large cell neuroendocrine carcinoma and the role of LIPI in immunological stratification.
Lung Cancer
August 2025
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; National Center for Respiratory Medicine, National Clinical Research Center for Respiratory Disease, State Key Laboratory of Respiratory Disease, Guangzhou, China; Guangzhou Institute of Respiratory Health, Guangzhou, C
Background: Large cell neuroendocrine carcinoma (LCNEC) represents a rare and unique type of lung tumor with an unfavorable prognosis. It is essential to summarize the treatment modalities and prognosis for inoperable stage III and IV LCNEC, explore the role of frontline immunotherapy, and examine the stratification role of the Lung Immune Prognostic Index (LIPI) and its relationship with the tumor microenvironment (TME).
Methods: This study retrospectively analyzed 160 patients with inoperable lung LCNEC (L-LCNEC) admitted to three hospitals from December 2012 to November 2023.
Scoping Review of Operative Management of Thoracic Malignancies in Patients With Psychiatric Comorbidities.
J Surg Res
September 2025
Department of Surgery, Keck School of Medicine of USC, Los Angeles, California. Electronic address:
Introduction: Psychiatric comorbidities are increasingly recognized in patients with thoracic malignancies. We undertook this scoping review to characterize the management of thoracic malignancies in patients with psychiatric illness and uncover any disparities in operative treatment or perioperative outcomes.
Methods: We conducted a scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Identifying meaningful drug response biomarkers from public pharmacogenomic datasets with biologically informed interpretable neural networks.
Comput Biol Chem
September 2025
Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macao Special Administrative Region of China. Electronic address:
With the advancements of next-generation sequencing, publicly available pharmacogenomic datasets from cancer cell lines provide a handle for developing predictive models of drug responses and identifying associated biomarkers. However, many currently available predictive models are often just used as black boxes, lacking meaningful biological interpretations. In this study, we made use of open-source drug response data from cancer cell lines, in conjunction with KEGG pathway information, to develop sparse neural networks, K-net, enabling the prediction of drug response in EGFR signaling pathways and the identification of key biomarkers.
View Article and Find Full Text PDFAmrubicin monotherapy for refractory, relapsed, small cell lung cancer in elderly patients.
Jpn J Clin Oncol
September 2025
Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Background: Amrubicin monotherapy has been used in Japan for patients with refractory, relapsed, small cell lung cancer (SCLC). However, the clinical guidelines do not specify a recommended initial dose for elderly patients. This retrospective study aimed to explore the appropriate initial dose of amrubicin for elderly patients with refractory, relapsed SCLC.
View Article and Find Full Text PDFLabel-free immunoassay based on chemiluminescence-functionalized magnetic mesoporous nanoparticles for rapid detection of neuron-specific enolase.
Mikrochim Acta
September 2025
The Third Affiliated Hospital of Anhui Medical University, The First People's Hospital of Hefei, Binhu Hospital of Hefei, Hefei, 230061, P. R. China.
Lung cancer, as one of the cancers with the highest morbidity and mortality rates in the world, requires accurate detection of its vital serum marker, neuron-specific enolase (NSE), which is a key challenge for early detection of lung cancer. However, traditional chemiluminescence immunoassay (CLIA) methods rely on labeled antibodies (Abs) and suffer from complex operations and high costs. In this work, a label-free CLIA based on CL-functionalized mesoporous magnetic nanoparticles (CuFeO@mSiO-Cys-Luminol-Au NPs) is developed for the rapid and sensitive detection of NSE.
View Article and Find Full Text PDF